Predicting Effective Therapy in Pancreatic Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Cancer, Pancreatic Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/2/2019 |
| Start Date: | January 24, 2017 |
| End Date: | January 24, 2020 |
| Contact: | Kenneth Yu, M.D. |
| Email: | yuk1@mskcc.org |
| Phone: | 646-888-4188 |
Circulating Tumor Cell and Tumor Tissue Models for Predicting Effective Pancreatic Cancer Response
The purpose of this phase II study is to develop a test to predict response of pancreatic
cancer to different chemotherapy regimens.
cancer to different chemotherapy regimens.
Inclusion Criteria:
- Histological or cytological diagnosis of pancreatic adenocarcinoma, confirmed at
MSKCC, AJCC stage IV disease at time of enrollment.
- Patient planning to receive treatment with FOLFIRINOX or gem/nab-P chemotherapy, with
or without investigational agents.
- Prior surgery, chemotherapy and/or radiation therapy for AJCC Stage I-III pancreatic
adenocarcinoma is permitted.
- ECOG performance status 0-2.
- A minimum age of 18 years old.
Exclusion Criteria:
- Prior chemotherapy for AJCC stage IV pancreatic adenocarcinoma
- Known to be HIV positive on antiretroviral therapy
- Prior organ allograft
- Any medical or psychiatric condition that may interfere with the ability to comply
with protocol procedures
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
1000 N Village Ave
Rockville Centre, New York 11570
Rockville Centre, New York 11570
(516) 256-3600
Phone: 646-888-4188
Memorial Sloan-Kettering at Mercy Medical Center Memorial Sloan Kettering Cancer Center Rockville Centre provides state-of-the-art...
Click here to add this to my saved trials